Open AccessCoagulation profile in myeloproliferative Neoplasms.
Author(s) -
Sadia Taj,
Mona Aziz,
Maliha Asif,
Amna Arooj,
Madiha Islam,
Adnan Tariq
Publication year - 2020
Publication title -
the professional medical journal/the professional medical journal
Language(s) - English
Resource type - Journals
eISSN - 2071-7733
pISSN - 1024-8919
DOI - 10.29309/tpmj/2020.27.05.3864
Subject(s) - medicine , myelofibrosis , thrombocytosis , polycythemia vera , partial thromboplastin time , prothrombin time , myeloproliferative neoplasm , gastroenterology , coagulation testing , coagulation , myeloproliferative disorders , surgery , platelet , bone marrow
Objectives: Evaluation of coagulation profile in patients with Myeloproliferative Neoplasms. Study Design: Cross sectional survey. Setting: Department of Haematology, Shaikh Zayed Hospital, Lahore. Period: From 10-03-2015 to 09-03-2016. Materials & Methods: A total of 55 patients of myeloproliferative neoplasms (Chronic Myeloid leukaemia, Polycythemia vera, Essential thrombocytosis and Primary Myelofibrosis) were studied over 1 year period. Patients of >15 yrs and both the genders were included. Patients already on anticoagulation and liver disease were excluded. All patients underwent screening of PT, APTT and D-dimer. PT and APTT was measured by KC4 Amelung coagulometer and D-Dimer by Latex Kit 60X. Results: Twenty four of 55 cases (43.64%) of myeloproliferative neoplasms had elevated Prothrombin time. Activated partial thromboplastin time was elevated in 18 of 55 (32.73%) cases and D-Dimer was elevated in 11 of 55 (20%) cases. Conclusion: CML is statistically the most spreading form of MPN and ET is least common form in comparison with other MPNs. Thrombohaemorrhagic complications significantly affect the morbidity and mortality of MPN patients which can be assessed by coagulation studies. Timely diagnosis of these prothrombotic/haemorrhagic states can decrease the morbidity in these patients